Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Comment by joe_trouton Aug 25, 2011 7:18pm

233 Views

Post# 18980488

RE: RE: RE: The Interview.

Didn't look like the type of format he was comfortable in is all. Many shareholders are finicky too. They are easy to scatter off in a panic. That's why they have those black box trading platforms in the exchange server rooms, front running customers, and throwing their financial weight around to extract their gains off of weak shareholders.

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!